Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Susan Alpert

This article was originally published in The Gray Sheet

Executive Summary

Former director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health will join C.R. Bard as VP-regulatory sciences, effective Oct. 1. Alpert served as ODE director for six years before transferring to FDA's Center for Food Safety and Applied Nutrition in October 1999 as director of food safety. Alpert, who holds both an MD and PhD, first joined FDA in 1987 as supervisory medical officer at the agency's Center for Drug Evaluation and Research. The title of ODE director, which has been held by CDRH Director David Feigal on an interim basis since Alpert's departure from ODE, is being passed to Bernard Statland. Appointed June 16, Statland assumes his new duties the week of July 17 (1"The Gray Sheet" June 19, p. 2)
Advertisement

Related Content

FDA Device Center Taps Agency Outsider Statland For Top ODE Post
FDA Device Center Taps Agency Outsider Statland For Top ODE Post
Advertisement
UsernamePublicRestriction

Register

MT013619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel